Swiss National Bank cut its position in shares of Clorox Company (The) (NYSE:CLX) by 0.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 910,592 shares of the company’s stock after selling 4,500 shares during the period. Swiss National Bank owned 0.71% of Clorox Company (The) worth $121,327,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Clorox Company (The) by 4.8% in the first quarter. Vanguard Group Inc. now owns 14,164,716 shares of the company’s stock worth $1,909,829,000 after buying an additional 649,766 shares during the period. BlackRock Inc. boosted its stake in Clorox Company (The) by 1,402.2% in the first quarter. BlackRock Inc. now owns 10,390,206 shares of the company’s stock worth $1,400,912,000 after buying an additional 9,698,542 shares during the period. State Street Corp boosted its stake in Clorox Company (The) by 2.2% in the first quarter. State Street Corp now owns 7,648,999 shares of the company’s stock worth $1,031,304,000 after buying an additional 167,689 shares during the period. Parnassus Investments CA acquired a new stake in Clorox Company (The) during the first quarter worth approximately $434,255,000. Finally, Valueinvest Asset Management S.A. boosted its stake in Clorox Company (The) by 6.9% in the first quarter. Valueinvest Asset Management S.A. now owns 1,580,400 shares of the company’s stock worth $213,085,000 after buying an additional 102,300 shares during the period. Institutional investors own 71.26% of the company’s stock.

Clorox Company (NYSE CLX) opened at 138.53 on Friday. The stock has a 50 day moving average price of $134.72 and a 200 day moving average price of $135.01. The stock has a market capitalization of $17.88 billion, a PE ratio of 25.97 and a beta of 0.40. Clorox Company has a 52 week low of $111.24 and a 52 week high of $141.76.

Clorox Company (The) (NYSE:CLX) last announced its earnings results on Thursday, August 3rd. The company reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.04. The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.65 billion. Clorox Company (The) had a return on equity of 190.67% and a net margin of 11.74%. The business’s revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.30 EPS. Equities analysts forecast that Clorox Company will post $5.68 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/clorox-company-the-clx-shares-sold-by-swiss-national-bank/1535981.html.

A number of equities research analysts have commented on CLX shares. BidaskClub cut Clorox Company (The) from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Zacks Investment Research upgraded Clorox Company (The) from a “hold” rating to a “buy” rating and set a $149.00 price target for the company in a research note on Tuesday, July 4th. Deutsche Bank AG reiterated a “hold” rating and issued a $137.00 price target (up from $126.00) on shares of Clorox Company (The) in a research note on Saturday, July 22nd. BMO Capital Markets reiterated a “buy” rating and issued a $136.00 price target on shares of Clorox Company (The) in a research note on Thursday, May 4th. Finally, UBS AG reiterated a “sell” rating and issued a $121.00 price target (up from $117.00) on shares of Clorox Company (The) in a research note on Friday, May 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $129.05.

In related news, EVP James E. Foster sold 9,861 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $138.51, for a total value of $1,365,847.11. Following the completion of the sale, the executive vice president now directly owns 22,069 shares of the company’s stock, valued at approximately $3,056,777.19. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Jon M. Balousek sold 9,223 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $138.87, for a total value of $1,280,798.01. Following the completion of the sale, the senior vice president now directly owns 20,614 shares of the company’s stock, valued at $2,862,666.18. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,242 shares of company stock valued at $2,944,449. Insiders own 0.74% of the company’s stock.

Clorox Company (The) Company Profile

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Institutional Ownership by Quarter for Clorox Company (The) (NYSE:CLX)

Receive News & Ratings for Clorox Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.